Spyre Therapeutics Launches New $500M At-The-Market Offering, Upsizing Previous Program
SYRE has more than doubled off its 52-week low of $14 on elevated volume (2.6× avg).
Summary
Spyre Therapeutics launched a new At-The-Market (ATM) offering to sell up to $500 million of common stock, replacing a smaller prior program. The capital will fund ongoing clinical trials and R&D.
Key Events · Financing and Capital Events · SYRE
-
New At-The-Market (ATM) Offering
Spyre Therapeutics established a new ATM program to sell up to $500 million of common stock through TD Securities (USA) LLC (TD Cowen).
-
Upsized Capital Raise
This new program replaces a previous ATM offering (which had $36.55 million in unsold securities carried forward from a February 2026 registration), significantly increasing the potential capital available to the company.
-
Funding for Clinical Programs
Proceeds will primarily fund preclinical studies, clinical trials, and manufacturing for its IBD and RD antibody programs, as well as general corporate purposes.
-
Potential Share Dilution
The offering is expected to result in immediate and substantial dilution for existing shareholders, as disclosed in the filing.
Analysis · SYRE · Life Sciences
Spyre Therapeutics has established a new At-The-Market (ATM) offering program to sell up to $500 million in common stock. This new program replaces a prior ATM offering, significantly increasing the potential capital available to the company. The proceeds are earmarked to advance its IBD and RD antibody programs, including funding preclinical studies, clinical trials, and manufacturing. This substantial capital raise, following recent positive Phase 2 clinical data for SPY001 and SPY002, provides a significant runway for the company's drug development efforts, although it will result in dilution for existing shareholders.
At the time of this filing, SYRE was trading at $87.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $14.00 to $102.06. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.